Get the Stockscreener App
0.9766
6.10%
-0.0634
After Hours:
.98
0.0034
+0.35%
Outlook Therapeutics Inc stock is traded at $0.9766, with a volume of 8.08M.
It is down -6.10% in the last 24 hours and down -38.58% over the past month.
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
See More
Previous Close:
$1.04
Open:
$1.01
24h Volume:
8.08M
Relative Volume:
0.41
Market Cap:
$182.62M
Revenue:
$424.90K
Net Income/Loss:
$-94.02M
P/E Ratio:
-0.3931
EPS:
-2.4842
Net Cash Flow:
$-51.25M
1W Performance:
-30.49%
1M Performance:
-38.58%
6M Performance:
+122.11%
1Y Performance:
-50.17%
1-Day Range:
$0.9283
$1.035
1-Week Range:
$0.82
$1.42
52-Week Range:
$0.1611
$3.39
Outlook Therapeutics Inc Stock (OTLK) Company Profile
Name
Outlook Therapeutics Inc
Sector
Industry
Phone
(609) 619-3990
Address
111 S. WOOD AVENUE, ISELIN, NJ
Compare OTLK vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OTLK
Outlook Therapeutics Inc
|
0.9766 | 199.15M | 424.90K | -94.02M | -51.25M | -2.4842 |
VRTX
Vertex Pharmaceuticals Inc
|
477.10 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
762.63 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
853.82 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
187.53 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
316.01 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
Outlook Therapeutics Inc Stock (OTLK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-29-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Aug-28-25 | Downgrade | Guggenheim | Buy → Neutral |
| Dec-02-24 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Mar-27-24 | Upgrade | BTIG Research | Neutral → Buy |
| Feb-15-24 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Jan-25-24 | Upgrade | Guggenheim | Neutral → Buy |
| Dec-27-23 | Upgrade | CapitalOne | Equal Weight → Overweight |
| Aug-31-23 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Aug-31-23 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Aug-30-23 | Downgrade | BTIG Research | Buy → Neutral |
| Aug-30-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Aug-30-23 | Downgrade | CapitalOne | Overweight → Equal Weight |
| Aug-30-23 | Downgrade | Guggenheim | Buy → Neutral |
| Jul-13-23 | Initiated | CapitalOne | Overweight |
| Apr-03-23 | Initiated | Guggenheim | Buy |
| Feb-06-23 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-31-22 | Initiated | BTIG Research | Buy |
| Sep-13-22 | Initiated | Chardan Capital Markets | Buy |
| Sep-11-19 | Initiated | Ladenburg Thalmann | Buy |
| May-16-19 | Initiated | Oppenheimer | Outperform |
| Apr-22-19 | Initiated | Ascendiant Capital Markets | Buy |
View All
Outlook Therapeutics Inc Stock (OTLK) Latest News
Outlook Therapeutics Stock (OTLK) Opinions on Analyst Upgrades - Quiver Quantitative
Outlook Therapeutics scores landmark FDA win to launches first ophthalmic bevacizumab for wet AMD - Indian Pharma Post
OTLK|Outlook Therapeutics Inc|Price:1.065|Chg%:-0.340 - TradingKey
Outlook Therapeutics wins FDA nod for Lytenava in neovascular AMD - Indian Pharma Post
Outlook Therapeutics Inc (OTLK) Institutional Confidence - TradingKey
OTLK Upgraded by BTIG -- Price Target Announced at $4.00 - GuruFocus
OTLK Maintained by HC Wainwright & Co. -- Price Target Raised to $1.60 - GuruFocus
Outlook Therapeutics’ Recently Approved Therapy Could Become Preferred Anti-VEGF Treatment Option In $8.5B US Retina Market, Says BTIG - Stocktwits
These 3 Stocks Led Wall Street’s Biggest Gains On Tuesday – Here’s Why - Stocktwits
Outlook Therapeutics Targets Multibillion Dollar Ophthalmology Market With New Drug After FDA Rejection - Benzinga
BTIG upgrades Outlook Therapeutics stock rating on FDA approval - Investing.com
FDA nod for Outlook Therapeutics’ Lytenava at last - The Pharma Letter
This General Motors Analyst Turns Bulish; Here Are Top 5 Upgrades For Monday - Benzinga
Outlook Therapeutics wins FDA approval for Lytenava in wet AMD - Yahoo Finance
Outlook Therapeutics shares climb after FDA clears LYTENAVA for wet AMD - Yahoo Finance
BTIG upgrades Outlook Therapeutics stock rating on FDA approval By Investing.com - Investing.com Canada
Why is Outlook Therapeutics stock surging today? By Investing.com - Investing.com Canada
Outlook Therapeutics Inc (OTLK) Valuation: PE, PB & Fair Value Analysis - TradingKey
OTLK Stock Jumps Overnight After FDA Approval Of Wet AMD Drug — Analysts See Nearly 300% Upside - Stocktwits
FDA Approves Outlook Therapeutics’ Lytenava to Treat Wet AMD - VisionMonday.com
Outlook Therapeutics Inc (OTLK) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
OTLK Stock Surges After FDA Ends Decade-Long Wait For Ophthalmic Bevacizumab - Stocktwits
OTLK Stock Soars 28% After FDA Sets July Date For Lytenava Decision - Stocktwits
Outlook Therapeutics Inc (OTLK) Income Statement - TradingKey
OTLK Stock Surges On FDA Lytenava Application Resubmission After Successful Appeal - Stocktwits
FDA Finally Clears Outlook Therapeutics' Lytenava, But the Cash Crunch Looms Large - AD HOC NEWS
Outlook Therapeutics Grants Incentive Awards Tied to FDA Approval - The Globe and Mail
Outlook Therapeutics Inc (OTLK) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
US FDA approves Outlook Therapeutics’ eye disease drug - KWSN
Outlook Therapeutics (OTLK) Receives FDA Approval for Lytenava i - GuruFocus
Outlook Therapeutics (OTLK) Secures FDA Approval for Lytenava in Wet AMD Treatment - GuruFocus
OTLK Stock Surges 24% Following FDA Approval for AMD Treatment - GuruFocus
Outlook Therapeutics Gains FDA Approval for LYTENAVA Launch - TipRanks
US FDA approves Outlook Therapeutics' eye disease drug - Reuters
OTLK Stock Slips After Regaining Nasdaq Compliance - timothysykes.com
FDA approves Outlook Therapeutics' LYTENAVA for the treatment of wet AMD - Ophthalmology Times Europe
Outlook Therapeutics (OTLK) Receives FDA Approval for Lytenava in Wet AMD Treatment - GuruFocus
Outlook Therapeutics (NASDAQ:OTLK) suspended post-Lytenava approval, with funding under pressure from looming warrants - TechStock²
Outlook Therapeutics receives FDA approval for wet AMD treatment - Investing.com
Outlook Therapeutics Says Lytenava Gets FDA Approval for Retinal Disease Treatment - marketscreener.com
FDA Approves Outlook Therapeutics' Lytenava as First Ophthalmic Bevacizumab for Wet AMD - Eyewire+
Outlook Therapeutics Announces LYTENAVA FDA Approval For Treatment Of Wet AMD - TradingView
US-FDA genehmigt Medikament von Outlook Therapeutics gegen Augenerkrankungen - TradingView
Outlook Therapeutics Announces LYTENAVA™ FDA Approval as - GlobeNewswire
Outlook Therapeutics, Inc. Revenue Breakdown – SWB:41O - TradingView
Outlook Therapeutics grants options to CEO Robert C. Jahr and CFO Lawrence A. Kenyon - TradingView
Form 4 OUTLOOK THERAPEUTICS INC For: 23 July By Investing.com - Investing.com Nigeria
Outlook Therapeutics grants CEO, CFO options at $1.43 per share - Bitget
Outlook Therapeutics Inc Stock (OTLK) Financials Data
Revenue
Net Income
Cash Flow
EPS
Outlook Therapeutics Inc Stock (OTLK) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Haddadin Yezan Munther | Director |
Jun 02 '26 |
Buy |
0.83 |
29,000 |
24,145 |
66,167 |
| Sukhtian Ghiath M. | Director |
May 28 '26 |
Buy |
0.59 |
8,539,709 |
5,000,000 |
22,092,068 |
| Sukhtian Faisal Ghiath | Director |
May 27 '26 |
Buy |
0.41 |
122,174 |
50,006 |
125,574 |
| Haddadin Yezan Munther | Director |
May 26 '26 |
Buy |
0.44 |
34,000 |
14,960 |
37,167 |
| THURMAN RANDY H | Director |
May 26 '26 |
Buy |
0.43 |
5,000 |
2,145 |
5,593 |
| HILZINGER KURT J | Director |
May 26 '26 |
Buy |
0.44 |
400,000 |
176,520 |
423,655 |
2.44%
0.02%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):